Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki‐67 Is ≥10%?

BACKGROUND: Long‐acting somatostatin analogs (SSAs) are the primary first‐line treatment of well‐differentiated advanced gastroenteropancreatic neuroendocrine tumors (NETs), but data about their efficacy in pancreatic NETs (panNETs) with Ki‐67 ≥10% are still limited. MATERIALS AND METHODS: To assess...

Full description

Saved in:
Bibliographic Details
Published in:Oncologist
Main Authors: Merola, Elettra, Alonso Gordoa, Teresa, Zhang, Panpan, Al‐Toubah, Taymeyah, Pellè, Eleonora, Kolasińska‐Ćwikła, Agnieszka, Zandee, Wouter, Laskaratos, Faidon, de Mestier, Louis, Lamarca, Angela, Hernando, Jorge, Cwikla, Jaroslaw, Strosberg, Jonathan, de Herder, Wouter, Caplin, Martin, Cives, Mauro, van Leeuwaarde, Rachel
Format: Artigo
Language:Inglês
Published: John Wiley & Sons, Inc. 2020
Subjects:
Gastrointestinal Cancer
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8018333/
https://ncbi.nlm.nih.gov/pubmed/33301235
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13633
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items